New drug for chronic hives begins first human safety tests
NCT ID NCT07230418
First seen Nov 17, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This early-stage trial tests the safety and tolerability of a new drug called HRS-3095 in 66 healthy adults aged 18-55. Researchers will also study how the drug moves through the body and how food affects it. The goal is to gather essential safety data before testing the drug in people with chronic spontaneous urticaria (long-term hives). No treatment benefit is expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Frist Clinical Medicial College of Qingdao University
RECRUITINGQingdao, Shandong, 266555, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.